HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Journal articles

Development of metronidazole-resistant lines of Blastocystis sp.

Abstract : Metronidazole (MTR) is frequently used for the treatment of Blastocystis infections, but with variable effectiveness, and often with treatment failures as a possible result of drug resistance. We have developed two Blastocystis MTR-resistant (MTRR) subtype 4 WR1 lines (WR1-M4 and WR1-M5), with variable susceptibility to a panel of anti-protozoal agents including various 5-nitroimidazoles, nitazoxanide and furazolidone. WR1-M4 and WR1-M5 were developed and assessed over an 18-month period and displayed persistent MTR resistance, being more than 2.5-fold less susceptible to MTR than the parent isolate. The MTRR lines grew with a similar g time to WR1, but were morphologically less consistent with a mixture of size. All Blastocystis isolates and the MTRR lines were most susceptible to the 5-nitroimidazole drug ronidazole. WR1-M5 was apparently cross-resistant to satranidazole and furazolidone, and WR1-M4 was cross-resistant to nitazoxanide. These MTRR lines now provide a valuable tool for the continued assessment of the efficacy and mechanism of action of new and established drugs against a range of Blastocystis sp. subtypes, in order to identify a universally effective drug and to facilitate understanding of the mechanisms of drug action and resistance in Blastocystis.
Document type :
Journal articles
Complete list of metadata

Contributor : Didier Gigmes Connect in order to contact the contributor
Submitted on : Tuesday, February 7, 2017 - 4:35:31 PM
Last modification on : Thursday, November 4, 2021 - 3:24:27 AM

Links full text




L. A. Dunn, K. S. W. Tan, P. Vanelle, T. Juspin, M. D. Crozet, et al.. Development of metronidazole-resistant lines of Blastocystis sp.. Parasitology Research, Springer Verlag (Germany), 2012, 111 (1), pp.441--450. ⟨10.1007/s00436-012-2860-7⟩. ⟨hal-01460365⟩



Record views